Cargando…
The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy
BACKGROUND: Colorectal carcinoma (CRC) with CpG island methylator phenotype (CIMP) is recognized as a distinct subgroup of CRC, and CIMP status affects prognosis and response to chemotherapy. Identification of CIMP status in CRC is important for proper patient management. In Eastern countries, howev...
Autores principales: | Min, Byung-Hoon, Bae, Jeong Mo, Lee, Eui Jin, Yu, Hong Suk, Kim, Young-Ho, Chang, Dong Kyung, Kim, Hee Cheol, Park, Cheol Keun, Lee, Suk-Hee, Kim, Kyoung-Mee, Kang, Gyeong Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162585/ https://www.ncbi.nlm.nih.gov/pubmed/21827707 http://dx.doi.org/10.1186/1471-2407-11-344 |
Ejemplares similares
-
Methylation Profiles of CpG Island Loci in Major Types of Human Cancers
por: Park, Seog-Yun, et al.
Publicado: (2007) -
The Role of the CpG Island Methylator Phenotype on Survival Outcome in Colon Cancer
por: Kang, Ki Joo, et al.
Publicado: (2015) -
CpG Island Hypermethylation in Gastric Carcinoma and Its Premalignant Lesions
por: Kang, Gyeong Hoon
Publicado: (2012) -
CpG Island Methylation in Familial Colorectal Cancer Patients Not Fulfilling the Amsterdam Criteria
por: Kim, Hee Cheol, et al.
Publicado: (2008) -
Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX
por: Lee, Dae-Won, et al.
Publicado: (2015)